Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
18597586
DOI
10.33549/physiolres.931506
PII: 1506
Knihovny.cz E-zdroje
- MeSH
- acetylcholin farmakologie MeSH
- časové faktory MeSH
- cévní endotel účinky léků patofyziologie MeSH
- diabetické angiopatie patofyziologie prevence a kontrola MeSH
- experimentální diabetes mellitus farmakoterapie patofyziologie MeSH
- glykosaminoglykany farmakologie MeSH
- hypoglykemika farmakologie MeSH
- krevní glukóza účinky léků MeSH
- krysa rodu Rattus MeSH
- potkani Wistar MeSH
- vazodilatace účinky léků MeSH
- vazodilatancia farmakologie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- acetylcholin MeSH
- glucuronyl glucosamine glycan sulfate MeSH Prohlížeč
- glykosaminoglykany MeSH
- hypoglykemika MeSH
- krevní glukóza MeSH
- vazodilatancia MeSH
Diabetes mellitus is associated with many complications including retinopathy, nephropathy, neuropathy and angiopathy. Increased cardiovascular risk is accompanied with diabetes-induced endothelial dysfunction. Pharmacological agents with endothelium-protective effects may decrease cardiovascular complications. In present study sulodexide (glycosaminoglycans composed from heparin-like and dermatan fractions) was chosen to evaluate its protective properties on endothelial dysfunction in diabetes. Effect of sulodexide treatment (SLX, 100 UI/kg/day, i.p.) in 5 and 10 weeks lasting streptozotocin-induced diabetes (30 mg/kg/day, i.p. administered for three consecutive days) was investigated. Animals were divided into four groups: control (injected with saline solution), control-treated with sulodexide (SLX), diabetic (DM) and diabetic-treated with sulodexide (DM+SLX). The pre-prandial and postprandial plasma glucose levels, number of circulating endothelial cells (EC) and acetylcholine-induced relaxation of isolated aorta and mesenteric artery were evaluated. Streptozotocin elicited hyperglycemia irrespective of SLX treatment. Streptozotocin-induced diabetes enhanced the number of circulating endothelial cells compared to controls. SLX treatment decreased the number of EC in 10-week diabetes. Acetylcholine-induced relaxation of mesenteric arteries was significantly impaired in 5 and 10-week diabetes. SLX administration improved relaxation to acetylcholine in 5 and 10-week diabetes. Diabetes impaired acetylcholine-induced relaxation of rat aorta irrespective of SLX treatment. Our results demonstrate that SLX treatment lowers the number of circulating endothelial cells and improves endothelium-dependent relaxation in small arteries. These findings suggest endothelium-protective effect of sulodexide in streptozotocin-induced diabetes.
Citace poskytuje Crossref.org
Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis
